[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]  Neuroscience News [@NeuroscienceNew](/creator/twitter/NeuroscienceNew) on x 504.3K followers Created: 2025-07-14 20:10:01 UTC Cancer Drug Shows Promise In Treating AMD Vision Loss Researchers have discovered that a cancer drug originally developed for tumors could help prevent blindness. PRL3-zumab, developed at A*STAR, was shown in pre-clinical studies to reduce leakage from damaged blood vessels in the eye, a key cause of vision loss in wet age-related macular degeneration and diabetic retinopathy. Unlike current therapies requiring frequent, risky eye injections, PRL3-zumab can be administered intravenously and showed an XX% greater reduction in leakage. The intravenous method also maintained therapeutic levels in the eye for longer and may reduce complications. With human trials approved and planned for late 2025, the drug offers hope to patients who don’t respond well to current treatments. The findings highlight how cancer research can lead to breakthroughs in unexpected fields like ophthalmology.  XXXXX engagements  **Related Topics** [advanced micro devices](/topic/advanced-micro-devices) [stocks technology](/topic/stocks-technology) [Post Link](https://x.com/NeuroscienceNew/status/1944851900958171354)
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
Neuroscience News @NeuroscienceNew on x 504.3K followers
Created: 2025-07-14 20:10:01 UTC
Cancer Drug Shows Promise In Treating AMD Vision Loss
Researchers have discovered that a cancer drug originally developed for tumors could help prevent blindness.
PRL3-zumab, developed at A*STAR, was shown in pre-clinical studies to reduce leakage from damaged blood vessels in the eye, a key cause of vision loss in wet age-related macular degeneration and diabetic retinopathy.
Unlike current therapies requiring frequent, risky eye injections, PRL3-zumab can be administered intravenously and showed an XX% greater reduction in leakage.
The intravenous method also maintained therapeutic levels in the eye for longer and may reduce complications.
With human trials approved and planned for late 2025, the drug offers hope to patients who don’t respond well to current treatments.
The findings highlight how cancer research can lead to breakthroughs in unexpected fields like ophthalmology.
XXXXX engagements
Related Topics advanced micro devices stocks technology